A recent study in Hacd2LKO mice has revealed ameliorated obesity, hepatic steatosis, and diabetes in HFD-treated mice, which were achieved by upregulating thermogenic genes to enhance energy expenditure, positioning Hacd2 as a therapeutic target [3]. This evidence concerns the gene HACD2 and diabetes mellitus.